Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Convalescent plasma therapy has been recognized as safe and plasma transfusion is routinely used in clinical practice. A recent study showed that early administration of convalescent plasma can decrease the risk of complications in specific high-risk population. The aim of the present study is to offer convalescent plasma therapy to immunocompromised patients and older adults in the early phase of a SARS-Cov-2 infection in order to accelerate viral clearance and prevent complication
Epistemonikos ID: 3fb1960768e00fd8c5006ad076612e03785c61c4
First added on: Apr 09, 2021